2019 new anti ulcer drug
In 2019, several new anti-ulcer drugs were approved or launched in various regions. Here are a few examples:
- Tenapanor (Ibsrelvi): Approved by the US FDA in August 2019, Tenapanor is a first-in-class, oral medication that works by reducing the movement of sodium ions into the gut, which helps to reduce acid production and relieve symptoms of gastroesophageal reflux disease (GERD).
- Rilpivirine (Edurant): Although primarily used as an antiretroviral medication for HIV treatment, Rilpivirine has also been shown to have anti-ulcer properties. In 2019, it was approved by the European Medicines Agency (EMA) for the treatment of GERD in adults.
- Vilazodone (Viibryd): While not a new drug per se, Vilazodone was approved by the US FDA in 2009 for the treatment of major depressive disorder. In 2019, it was also approved for the treatment of GERD in adults.
- Gastric acid reducers: Several new gastric acid reducers were launched in 2019, including:
- Omeprazole (Zegerid): A delayed-release oral suspension approved by the US FDA for the treatment of GERD and erosive esophagitis.
- Lansoprazole (Prevacid 24HR): A delayed-release oral suspension approved by the US FDA for the treatment of GERD and erosive esophagitis.
- Rabeprazole (AcipHex 24HR): A delayed-release oral suspension approved by the US FDA for the treatment of GERD and erosive esophagitis.
Please note that this is not an exhaustive list, and the availability of these drugs may vary depending on your location and country. Additionally, it's always best to consult with a healthcare professional before starting any new medication.